Growth Hormone Peptides: A Secretagogue Evidence Roundup

Growth hormone (GH) secretagogues are compounds that make the body release more of its own growth hormone rather than replacing it from the outside. That is the key conceptual difference from recombinant human GH: a secretagogue only works if the pituitary gland can still respond, and it tends to preserve the natural rhythm of GH release along with the feedback loops that switch secretion off.

Almost every molecule in this space belongs to one of two mechanistic families.

• GHRH-receptor agonists. These are analogues of growth-hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to make and release GH. Sermorelin, tesamorelin, and CJC-1295 are the best-known examples. They bind the GHRH receptor on pituitary somatotroph cells.

• Ghrelin-receptor agonists. These act on a completely different receptor, the growth hormone secretagogue receptor type 1a (GHS-R1a), whose natural ligand is ghrelin—the so-called hunger hormone. This family includes the injectable growth-hormone-releasing peptides (GHRPs) such as GHRP-2, GHRP-6, and hexarelin, the more selective peptide ipamorelin, and orally active small molecules like ibutamoren (MK-677) and macimorelin.

Because the two families hit different receptors, they can act in a complementary way: GHRH analogues raise the amplitude of a GH pulse, while ghrelin agonists both trigger a pulse and blunt somatostatin, the brake on GH release. That synergy is the pharmacological rationale behind combining a GHRH analogue with a ghrelin agonist, though as later sections make clear, rationale is not the same as clinical evidence.

The GHRH-receptor pathway is the physiological one. When a GHRH analogue binds its receptor, it drives synthesis and pulsatile release of GH from somatotrophs, working with the ebb and flow of somatostatin to keep secretion episodic. Because sermorelin and its relatives are just stabilized versions of a natural signal, GH release stays under normal feedback control—if circulating GH and IGF-1 rise too high, the system tends to rein itself back in.

The ghrelin/GHS-R1a pathway is distinct and, in some respects, more forceful. Ghrelin-receptor agonists stimulate GH secretion by a mechanism separate from GHRH, and they also antagonize the release of somatostatin from the hypothalamus and pituitary—effectively releasing the brake at the same time as pressing the accelerator. This is why GHRPs can produce robust, sharp GH pulses.

The trade-off historically was specificity. The GHS-R1a receptor and related signaling are not perfectly confined to GH control, so first-generation peptides such as GHRP-6 and hexarelin also nudged cortisol, prolactin, and adrenocorticotropic hormone (ACTH), and GHRP-6 in particular is a strong appetite stimulant. A frequently cited advantage of ipamorelin, described in late-1990s preclinical work, was that it released GH comparably to GHRP-6 but with far less of that cortisol and prolactin spillover—making selectivity, rather than raw potency, its distinguishing feature.

Both families ultimately converge on the same downstream readout: a rise in GH, and then in insulin-like growth factor 1 (IGF-1), the liver-derived hormone that mediates many of GH's tissue effects and is the marker most studies actually measure.

Sermorelin (GRF 1-29) is the shortest fragment of GHRH that retains full activity—29 amino acids that bind the GHRH receptor and trigger physiological, pulsatile GH release. It has the deepest regulatory history of any molecule here. Sermorelin was FDA-approved in the 1990s under the brand name Geref, used both to evaluate pituitary GH reserve and to treat growth hormone deficiency in children with growth failure. The manufacturer discontinued Geref in 2008 for commercial, non-safety reasons; the U.S. FDA later formally determined it had not been withdrawn for safety or effectiveness problems. Today sermorelin has no approved branded product in the U.S. and circulates mainly through compounding pharmacies. Its practical limitation is a very short duration of action.

Tesamorelin is the standout success of the group. It is a stabilized GHRH(1-44) analogue carrying a trans-3-hexenoic acid group on its N-terminus that resists breakdown by the enzyme dipeptidyl peptidase-4 (DPP-4), giving it a longer, more sustained signal than native GHRH. Tesamorelin (brand name Egrifta) was FDA-approved in 2010 to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy—supported by Phase 3 randomized controlled trials showing selective loss of visceral adipose tissue and normalization of IGF-1. It remains the clearest example of a GH secretagogue with a rigorous, indication-specific evidence base.

CJC-1295 is a synthetic GHRH analogue best known in a version bearing a 'Drug Affinity Complex' (DAC) that binds serum albumin and dramatically extends its half-life, so a single dose can raise GH and IGF-1 for days. There is also a DAC-free variant often marketed simply as 'modified GRF 1-29.' Unlike sermorelin and tesamorelin, CJC-1295 has never been an approved medicine; its human data are limited to small, short pharmacology studies documenting elevated GH and IGF-1, not clinical-outcome trials.

The classic growth-hormone-releasing peptides came first. GHRP-6 was an early, potent GH releaser that also strongly stimulates appetite and modestly raises cortisol and prolactin. GHRP-2 (pralmorelin) is similarly potent and has actually been used diagnostically in some countries as a GH-stimulation agent. Hexarelin is among the most potent of the group but carries the greatest cross-reactivity with cortisol and prolactin, and its use in newer research has faded. None of these is an approved therapeutic in the United States.

Ipamorelin is the selective member of the family and the reason it became popular in the peptide world. Preclinical work characterized it as releasing GH with a clean profile—little of the cortisol, prolactin, or ACTH elevation that dogged earlier peptides—and without GHRP-6's strong appetite drive. That selectivity, not superior potency, is its documented distinction. Its human evidence base, however, remains thin; it was explored in early trials (including for post-operative gut motility) without becoming an approved product.

Two orally active ghrelin agonists deserve separate mention because they have real regulatory footprints. Macimorelin (Macrilen) is an orally available GHS-R1a agonist that was FDA-approved in December 2017 as a diagnostic test for adult growth hormone deficiency—patients drink it and clinicians measure the stimulated GH response over about 90 minutes, a far simpler procedure than the older insulin tolerance test. Ibutamoren (MK-677) is a non-peptide, orally active secretagogue that raises GH and IGF-1 and has been studied extensively, but it is not an approved drug and its development for indications such as GH deficiency and frailty did not culminate in approval.

It helps to sort the claims by how strong the underlying data really are.

Genuinely established (human, regulatory-grade): - Tesamorelin reduces visceral fat in HIV-associated lipodystrophy—Phase 3 RCT evidence, FDA-approved indication. - Macimorelin reliably provokes GH release for diagnosing adult GH deficiency—FDA-approved diagnostic. - Sermorelin raises GH and was historically used to treat pediatric GH deficiency and probe pituitary reserve.

Plausible but thinly evidenced (short trials, surrogate markers): - CJC-1295, ipamorelin, and MK-677 all reliably raise GH and IGF-1 in short human studies, and some show modest body-composition shifts—typically a small reduction in fat rather than a large gain in lean mass. These are pharmacodynamic effects on blood markers, not demonstrated improvements in strength, athletic performance, injury recovery, or longevity.

Largely unproven (extrapolation, animal, or in-vitro data, or no trials at all): - The widely promoted CJC-1295-plus-ipamorelin combination has essentially no published human randomized controlled trials evaluating meaningful outcomes; its appeal rests on mechanistic synergy and marketing rather than clinical proof. - Anti-aging, deep-sleep, skin, and general 'wellness' claims are mostly inferences from IGF-1 changes or preclinical work.

The honest summary: raising GH and IGF-1 with a secretagogue is well documented, but the leap from 'IGF-1 went up' to a real-world benefit in an otherwise healthy adult is where the evidence thins out or disappears.

The theoretical safety argument for secretagogues over injected GH is that they preserve negative feedback. Because GH and IGF-1 still suppress further release, a working pituitary is less likely to be pushed to the extreme, sustained levels achievable with exogenous GH. GHRH analogues in particular keep secretion pulsatile and physiological.

That argument has limits. It assumes a healthy, responsive pituitary and does not eliminate the class-level concerns that come with elevating GH and IGF-1—fluid retention, joint aches, carpal-tunnel-type symptoms, and effects on insulin sensitivity and blood glucose are recognized with GH-axis stimulation generally. Ghrelin-receptor agonists add their own wrinkles: appetite stimulation (pronounced with GHRP-6), and, with the less selective peptides, cortisol and prolactin elevation. Long-term safety data for most of these compounds in healthy people simply do not exist, and the consequences of chronically raising IGF-1 over years are not well characterized.

An additional layer is product quality. Apart from the few approved medicines, most secretagogues sold for 'research' are not manufactured to pharmaceutical standards, so identity, purity, and dose can be uncertain—an issue that is about the supply chain rather than the molecule's intrinsic pharmacology.

The regulatory picture is easy to misread because a few of these molecules are real, approved drugs while the rest are not.

Approved medicines: tesamorelin (therapeutic, HIV-associated lipodystrophy), macimorelin (diagnostic, adult GH deficiency), and historically sermorelin (now without an approved U.S. product). Everything else—CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, and MK-677—is not an FDA-approved medicine, and products containing them are frequently labeled 'for research use only.'

Sport: all of these compounds are banned. The World Anti-Doping Agency prohibits GH secretagogues under category S2, and its list explicitly names GHRH and its analogues (including CJC-1295, sermorelin, and tesamorelin), ghrelin agonists and mimetics (including ibutamoren/MK-677, ipamorelin, macimorelin, and anamorelin), and the GHRPs (including GHRP-2/pralmorelin, GHRP-6, and hexarelin). They are prohibited at all times, in and out of competition, and anti-doping labs can detect them directly or through biomarker signatures such as altered GH pulsatility and IGF-1.

For anyone reading this as an athlete, the practical takeaway is unambiguous: this entire class will trigger an anti-doping violation.

The most useful mental model is a gradient of evidence, not a menu of interchangeable 'GH peptides.'

At one end sit the molecules that earned their place through controlled trials and regulatory review: tesamorelin for a specific metabolic indication and macimorelin as a diagnostic tool. These are legitimate pharmacology with defined uses. In the middle sits sermorelin—an approved drug in its day, with a coherent physiological mechanism, now living mostly in compounding pharmacies. At the far end sit the compounds that dominate online discussion—CJC-1295, ipamorelin, the GHRPs, and MK-677—where the pharmacology is real and reproducible at the level of blood markers, but the human outcome data are sparse to nonexistent, and the marketing runs far ahead of the science.

Two distinctions cut through most of the confusion. First, mechanism: is a compound a GHRH analogue or a ghrelin agonist? That predicts its receptor, its side-effect profile, and what it synergizes with. Second, evidence tier: is a claim backed by a randomized human trial, a short pharmacodynamic study, or just animal data and inference? Keeping those two axes straight turns a bewildering list of acronyms into a navigable map—and makes it obvious how much of the popular enthusiasm rests on the raising of a single lab value, IGF-1, rather than on demonstrated benefit.